Holen Sie sich die Stockscreener-App
14.30
2.66%
0.37
Handel nachbörslich:
14.30
Schlusskurs vom Vortag:
$13.93
Offen:
$13.99
24-Stunden-Volumen:
447.64K
Relative Volume:
0.55
Marktkapitalisierung:
$5.06B
Einnahmen:
$4.79B
Nettoeinkommen (Verlust:
$-317.00M
KGV:
-15.71
EPS:
-0.91
Netto-Cashflow:
$-59.00M
1W Leistung:
+4.30%
1M Leistung:
+21.91%
6M Leistung:
-16.23%
1J Leistung:
-17.34%
1-Tages-Spanne:
$13.91
$14.34
1-Wochen-Bereich:
$13.61
$14.34
52-Wochen-Spanne:
$10.45
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Vergleichen Sie BLCO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
14.30 | 4.85B | 4.79B | -317.00M | -59.00M | -0.91 |
|
ISRG
Intuitive Surgical Inc
|
511.00 | 183.59B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
181.28 | 51.10B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
88.66 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
267.40 | 36.95B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.90 | 15.88B | 2.90B | 467.20M | 306.90M | 6.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Medical Devices & SuppliesSpecialty Stocks Q1 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers - Yahoo Finance
What analysts say about Bausch + Lomb Corporation stockSuperior returns - jammulinksnews.com
Is Bausch + Lomb Corporation a good long term investmentUnmatched profit growth - jammulinksnews.com
What drives Bausch + Lomb Corporation stock priceTremendous gains - jammulinksnews.com
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie - Benzinga
Bausch + Lomb Insiders Added US$1.54m Of Stock To Their Holdings - 富途牛牛
RBC Capital Sticks to Their Buy Rating for Bausch + Lomb Corporation (BLCO) - The Globe and Mail
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $17 - 富途牛牛
Bausch + Lomb Q2 Earnings to Benefit From FX Tailwinds, Eye Drop Sales, RBC Says - MarketScreener
RBC Capital reiterates Outperform rating on Bausch & Lomb stock ahead of Q2 earnings - Investing.com Nigeria
RBC Capital reiterates Outperform rating on Bausch & Lomb stock ahead of Q2 earnings By Investing.com - Investing.com South Africa
Stifel reiterates Hold rating on Bausch & Lomb stock, maintains $12 price target - Investing.com Nigeria
Bausch & Lomb Corp (BLCO) Trading 4.96% Higher on Jun 30 - GuruFocus
Insider Stock Buying Reaches US$1.54m On Bausch + Lomb - Yahoo Finance
Bausch + Lomb Boosts Financing With €675 Million Note Offering - Finimize
Bausch & Lomb Corp (BLCO) Shares Up 3.89% on Jun 27 - GuruFocus
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility - Yahoo Finance
Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June - Yahoo Finance
Bausch + Lomb Upsizes Note Offering And Secures New Loans - Finimize
J.P. Morgan announces no stabilisation for Bausch + Lomb notes - Investing.com
Bausch + Lomb prices €675 million in senior secured notes - Investing.com
Bausch + Lomb Strengthens Financial Position with €675M Notes and $3.1B Credit Package - Stock Titan
Bausch + Lomb announces €600m senior secured notes offering - Investing.com
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering - DutchNews.nl
Bausch + Lomb Has Promising Growth, But Lower Entry Points Likely Soon - Seeking Alpha
Bausch + Lomb’s SWOT analysis: ophthalmology leader faces headwinds in stock outlook - Investing.com
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement - BioSpace
Bausch + Lomb (NYSE:BLCO) Price Target Cut to $16.00 by Analysts at Barclays - Defense World
Bausch + Lomb Unveils Massive $3B Financial Overhaul: €600M Notes Plus $3B Credit Facilities - Stock Titan
Bausch & Lomb (BLCO) Price Target Revised by Barclays Analyst | - GuruFocus
Bausch & Lomb (BLCO) Price Target Revised by Barclays Analyst | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Reduced by Barclays Analyst | - GuruFocus
Barclays reduces Bausch & Lomb stock price target to $16 - Investing.com Australia
Barclays reduces Bausch & Lomb stock price target to $16 By Investing.com - Investing.com Nigeria
BLCO Investors Have Opportunity to Join Bausch + Lomb Corporation Fraud Investigation with the Schall Law Firm - Business Wire
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities - GlobeNewswire Inc.
Bausch + Lomb (BLCO) Introduces New Lubricating Eye Drops in U.S - GuruFocus
Breakthrough Eye Drops: Bausch + Lomb Launches First-Ever Vitamin-Enriched Formula for Dry Eye Relief - Stock Titan
Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States - BioSpace
Bausch + Lomb Co. (NYSE:BLCO) Short Interest Update - Defense World
Bausch + Lomb Co. (NYSE:BLCO) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Bausch & Lomb Corp (BLCO) Trading Down 3.41% on May 30 - GuruFocus
Cetera Investment Advisers Decreases Stock Holdings in Bausch + Lomb Co. (NYSE:BLCO) - Defense World
Public market insider buying at Bausch + Lomb (BLCO) - The Globe and Mail
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know - Yahoo Finance
Bausch + Lomb’s SWOT analysis: stock outlook amid market challenges - Investing.com
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference - BioSpace
Bausch & Lomb shareholders approve board nominees and compensation - Investing.com
Bausch + Lomb shareholders elect 10 directors at annual meeting By Investing.com - Investing.com India
Bausch + Lomb shareholders elect 10 directors at annual meeting - Investing.com
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results - Yahoo Finance
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):